Insider Selling: Ralliant (NYSE:RAL) SVP Sells 2,530 Shares of Stock

Ralliant Corporation (NYSE:RAL) SVP Karen Bick sold 2,530 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $46.50, for a total value of $117,645.00. Following the sale, the senior vice president directly owned 42,652 shares in the company, valued at $1,983,318. This represents a 5.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ralliant Stock Performance

Shares of RAL traded up $0.33 during mid-day trading on Monday, reaching $44.97. The company had a trading volume of 1,595,371 shares, compared to its average volume of 2,034,404. The stock has a market capitalization of $5.03 billion and a P/E ratio of 22.94. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $57.02. The stock has a 50 day moving average of $48.94 and a two-hundred day moving average of $46.70. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million during the quarter, compared to analyst estimates of $543.04 million. Ralliant’s revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Investors of record on Monday, March 9th will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Ralliant’s dividend payout ratio is 10.20%.

Institutional Investors Weigh In On Ralliant

Large investors have recently made changes to their positions in the stock. Corient Private Wealth LLC lifted its position in Ralliant by 58.4% during the fourth quarter. Corient Private Wealth LLC now owns 24,191 shares of the company’s stock worth $1,232,000 after buying an additional 8,922 shares in the last quarter. Hsbc Holdings PLC increased its stake in shares of Ralliant by 230.2% in the 4th quarter. Hsbc Holdings PLC now owns 51,500 shares of the company’s stock worth $2,627,000 after acquiring an additional 35,902 shares during the last quarter. Storen Legacy Partners LLC purchased a new position in shares of Ralliant during the 4th quarter worth $314,000. Virtu Financial LLC acquired a new position in shares of Ralliant during the 4th quarter valued at about $221,000. Finally, T. Rowe Price Investment Management Inc. boosted its position in shares of Ralliant by 19.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,423,268 shares of the company’s stock valued at $174,279,000 after acquiring an additional 563,822 shares during the last quarter.

Analyst Ratings Changes

A number of research firms recently issued reports on RAL. Citigroup dropped their price target on shares of Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Morgan Stanley reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Ralliant in a research note on Friday, February 6th. Truist Financial lowered their price objective on Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Royal Bank Of Canada reduced their target price on Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday, February 6th. Finally, Barclays lowered their price target on Ralliant from $60.00 to $52.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $50.50.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.